Physician profile
Hong DO
NPI 1639683576
$17,819.61
in general payments reported to CMS, 2019-2025
32 companies · $3,906 in 2025
The $3,906 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,726 · 2022: $3,395 · 2023: $4,144 · 2024: $3,649 · 2025: $3,906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,186.59 |
| Education | $512.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,505.59 | 2021-2025 | |
| Amgen INC. | $2,408.53 | 2021-2025 | Otezla, Otezla |
| Genzyme Corporation | $1,604.29 | 2021-2025 | |
| Janssen Biotech, INC. | $1,155.88 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Lilly USA, LLC | $1,097.38 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,034.60 | 2021-2025 | Dupixent |
| Ucb, INC. | $947.88 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $725.25 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Novartis Pharmaceuticals Corporation | $714.44 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $632.42 | 2021-2025 | Cabtreo, Siliq, Jublia |
| Pfizer INC. | $599.52 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $546.87 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $546.78 | 2022-2024 | Vtama |
| Leo Pharma INC. | $546.05 | 2021-2025 | Adbry, Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $537.82 | 2022-2025 | Sotyktu |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $444.04 | 2022-2025 | |
| Incyte Corporation | $298.13 | 2021-2025 | Opzelura |
| Biofrontera INC. | $258.69 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $203.46 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $171.58 | 2022-2025 | Absorica Ld, Winlevi |
| Sanofi-Aventis U.S. LLC | $159.94 | 2021-2025 | |
| Botanix Sb INC | $156.43 | 2025 | Sofdra |
| Glaxosmithkline, LLC. | $121.62 | 2021 | |
| Epi Health, LLC | $99.22 | 2022 | |
| Almirall LLC | $69.42 | 2021-2022 | |
| Journey Medical Corporation | $68.43 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $48.51 | 2025 | Nuzyra |
| Sebela Pharmaceuticals INC. | $30.54 | 2021 | |
| Kyowa Kirin, INC. | $25.80 | 2024 | Poteligeo |
| Ani Pharmaceuticals, INC. | $21.16 | 2025 | Veregen |
| Vyne Pharmaceuticals INC. | $20.31 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $19.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hong DO listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.